about
Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type moleculesThermodynamics of fragment binding.A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligands.Structure-Based Consensus Scoring Scheme for Selecting Class A Aminergic GPCR Fragments.Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia.Thermodynamics guided lead discovery and optimization.The impact of binding thermodynamics on medicinal chemistry optimizations.Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery.Calculation of wave-functions with frozen orbitals in mixed quantum mechanics/molecular mechanics methods. Part I. Application of the Huzinaga equation.Validation of tautomeric and protomeric binding modes by free energy calculations. A case study for the structure based optimization of D-amino acid oxidase inhibitors.Force generation by titin folding.Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors.Optical Trapping Nanometry of Hypermethylated CPG-Island DNA.Structure Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray structures.II. Discovery of a novel series of CXCR3 antagonists with a beta amino acid core.I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines.Discovery of d-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation.Toward a consistent treatment of polarization in model QM/MM calculations.Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening.A road map for prioritizing warheads for cysteine targeting covalent inhibitorsThe active site of cytochrome P-450 nifedipine oxidase: a model-building studySynthesis and Biochemical Evaluation of Lid-Open D-Amino Acid Oxidase InhibitorsPrediction of carcinogenicity from molecular structure; modification and reinvestigation of the methodEstimation of impurity profiles of drugs and related materials. 12. Isolation and identification of an isomeric impurity in danazolInhibitors of lipid peroxidation among new pyrimido[1',6':1,2]pyrido[3,4-b]indoles[Structure-based drug design]Enthalpic efficiency of ligand bindingErratum to: A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligandsHow are fragments optimized? A retrospective analysis of 145 fragment optimizationsDiscovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitorsComparative Evaluation of Covalent Docking ToolsCatalytic Mechanism and Covalent Inhibition of UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA): Implications to the Design of Novel AntibacterialsThermodynamic profiling for fragment-based lead discovery and optimizationDrug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapiesA detailed mechanism of the oxidative half-reaction of d-amino acid oxidase: another route for flavin oxidationAllosteric activation of metabotropic glutamate receptor 5
P50
Q27652891-78AD608D-7A15-4ED1-92B0-7E7D5E8C2E68Q34212572-BA41E773-E690-46EB-BF46-BDB25F2DE7F2Q35345510-96434289-7546-46BF-B962-93764F2605E9Q35892490-CE4B8BD8-B799-438D-AADB-1354B55C6405Q36002153-E12247DF-7C52-4732-87F8-1F0CD724CEF5Q37783788-B870B2FE-A577-4351-B018-E0A3119B6FDDQ38542936-686C4957-87CC-4A16-9849-0BD6D14A5BB5Q39028995-EDE13B37-00CE-4296-9A12-9284D6539FE3Q39152309-BE67EABC-564A-42F4-9F96-81BDF997E92AQ43735325-EDEDB6B4-96F2-4E78-A1E0-3ABDBA7E0326Q47863372-661EB0F5-C74F-4497-B219-68CBF1E30ADDQ48049563-BAF7C05C-C620-4CAB-A4F1-4C193249CA8DQ48960093-39FDFB61-B963-4934-BF07-D7A6F1295C8DQ49635345-03A5E144-B8B6-4550-B468-B04AD7833D19Q49889517-DBAC9D24-234C-48A1-96C2-20BA9024D52DQ51358991-EC9D1E45-5E10-42E3-91EF-3B8161D22522Q51359006-63AC5D66-52D8-409E-B4FD-08DF646621DEQ52560424-C147B608-87F2-4BE0-8C4C-340D98161D9AQ53524928-914AC601-E1DC-44CD-A283-BA0E0ADD477BQ55033983-059A9F26-D6D9-4D6A-B073-A46355C6C4F0Q57482329-6FA4AADA-F8FD-47A8-AB8B-5058FDA0B26BQ57976088-360C464D-60F5-4005-93E9-FCB06EE94C65Q61818242-26199F7B-4A65-45E0-9395-8C26E657DF2BQ72018667-3C40B657-4DDF-4059-A77B-AA1CB0C7C0ADQ72320787-2E60AC8A-807D-4C5D-8479-E4ACB9EE2B77Q72483312-A9B88D40-0D14-49AC-811F-A7153C3E0A9FQ74402145-D0033403-411A-4B3C-87A2-1601B4A64414Q84659355-64D32203-BF92-4360-A9B4-8CB0488E5642Q85959848-FE2DA4CB-7CBE-4C9F-A689-E3CEC1FA29C3Q86198642-8619037E-C0D0-4E16-AF70-082D6DE7EB5EQ87854010-78FD9CBB-2EBB-4778-B493-65EF6AE41C83Q89063656-30D8718C-FF0E-4F9E-AE79-6B46B67C5630Q91245516-BA0F7589-7C59-47D2-83D1-1E01A5964751Q91332210-23C672A8-2B7C-4C11-A2DF-9B3B13EE316DQ91470123-76440CEE-A10B-4EE3-B8D0-46EEC6E9D755Q92588096-A63432FF-001F-49B5-908C-BD9EF36820E5Q93143956-6CE3374B-292F-4B57-A992-958793573BBF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
György G Ferenczy
@ast
György G Ferenczy
@en
György G Ferenczy
@es
György G Ferenczy
@nl
György G Ferenczy
@sl
type
label
György G Ferenczy
@ast
György G Ferenczy
@en
György G Ferenczy
@es
György G Ferenczy
@nl
György G Ferenczy
@sl
prefLabel
György G Ferenczy
@ast
György G Ferenczy
@en
György G Ferenczy
@es
György G Ferenczy
@nl
György G Ferenczy
@sl
P106
P21
P31
P496
0000-0002-5771-4616